In recent years, telehealth companies like Hims and Keeps have revolutionized access to hair loss treatments by offering ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high-growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% ...

The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.

More data on each subscriber which will feed into HIMS LLM MedMatch to increase personalization even more. Aside from cost and convenience, personalization is the key reason why HIMS has a ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations and gave upbeat guidance for 2025. But shares of the company dropped 19 ...

Hims & Hers stock fell by 27% as it announced plans to stop selling commercially available compounded semaglutide. The FDA removed semaglutide from its shortage list, affecting Hims & Hers' sales ...

Telehealth company Hims & Hers Health (NYSE ... affordability, and convenience for patients seeking healthcare services. These companies typically leverage digital platforms to offer services ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...